Non-pharmacological approaches

Early in the course of type 2 diabetes, it is possible for some people to achieve remission from the condition through weight loss. Remission is defined as HbA1c remaining below 48 mmol/mol or 6.5% for at least three months, without diabetes medication.52 Achieving remission reduces complications from type 2 diabetes and allows people to experience a greater quality of life.

Remission of type 2 diabetes is directly related to the amount of weight lost, with clinical trial data showing that the vast majority (85%) of trial participants who lost more than 15 kg achieved remission.53

The following is adapted from recommendation 5 (page 759) of Diabetes Canada clinical practice guideline on remission of type 2 diabetes.53

 

R

Low-calorie (~800 to 850 kcal/day) diets with meal replacement products for 3 to 5 months aimed at achieving >15 kg body weight loss, followed by structured food reintroduction and increased physical activity for weight-loss maintenance, and with behavioural support, should be considered for type 2 diabetes remission in non-pregnant adults.

The combination of weight loss and optimisation of lifestyle interventions is the primary intervention. Low-calorie diet, which has been well researched, is only one method of weight loss; other methods may be more appropriate. More research is required on the contribution of physical activity (which offers other physical and mental health benefits) to remission.

Behavioural and psychological support underpins delivery of a structured programme. Be aware of other conditions (such as eating disorders, see SIGN 164: Eating disorders) and screen and assess appropriately before starting an intensive weight-management programme.42

The aim is to achieve remission as soon as possible after diagnosis. Many people can achieve remission without a structured evidence-based programme if signposted to effective methods of weight loss. However, the additional support and professional input may be more beneficial for some. It is critical to understand individual motivations and social and personal circumstances, including other clinical conditions and access to services.

It is important to support individuals who enter a structured programme but do not achieve remission by emphasising the multiple benefits gained through clinically significant weight loss. This includes the positive effects of metabolic recovery; reduced blood pressure, blood lipids, polypharmacy and quality of life gained. Any weight loss should be considered a successful outcome. Equally, the importance of weight loss should be emphasised to individuals who do not wish to participate in a structured NHS programme.

Health boards across the NHS in Scotland currently deliver the Counterweight Plus structured type 2 diabetes remission programme, which was implemented as part of the Framework for the prevention, early detection and early intervention of type 2 diabetes and underpinned by guidance in the Public Health Scotland standards for weight management.42, 43

A review by SHTG found that  interim results from studies and large-scale pilots of digital-delivered programmes (with asynchronous messaging, educational content and health tracking) in NHS England suggest that both digital and in-person programmes can lead to similar levels of weight loss and remission and that type 2 diabetes programmes are cost effective to the NHS. Digital programmes have the potential to provide wider access to treatment and be more convenient to those particiipating.54 

Maintaining weight loss is critical to sustain remission.

 

Use standards for the delivery of tier 2 and tier 3 weight-management services for adults as a basis for design and delivery of structured weight-management programmes that include type 2 diabetes remission programmes (see Figure 3 in Components of an effective diabetes prevention programme).

 

Liaise with the primary care provider and local diabetes teams as appropriate to adjust both glucose-lowering and blood pressure lowering medication as part of the medicines management protocol in a type 2 diabetes remission programme.

 

Upon achieving remission, ensure the patient is coded in primary care systems correctly as being in remission of type 2 diabetes (Read code C10P1 Type II diabetes mellitus in remission). Patients should remain on the diabetes register for annual review, so retain the original type 2 diabetes code (C109-2). Do not use the code diabetes resolved’. It is reserved only for misdiagnosis or diabetes due to a secondary factor that has since been removed, such as acute steroid use.

Bariatric surgery

Bariatric and metabolic surgery (BMS), also referred to as weight-loss surgery, aims to help people lose significant weight by reducing the size of their stomach and altering gut hormones to make them feel less hungry and full more quickly.

The recommendations in this section are adapted from sections 1.10 and 1.11 of NICE guideline 246: Overweight and obesity management.26

 

R

Offer adults referral for multidisciplinary team assessment to ascertain if bariatric and metabolic surgery is suitable if they:

  • have prediabetes or type 2 diabetes
  • have received optimal non-surgical weight-management treatment
  • have a BMI greater than 35 kg/m2, or 32.5 kg/m2 where heritage includes South Asian, Chinese, other Asian, Middle Eastern, Black African, African-Caribbean or Arab family background
  • agree to the necessary long-term follow up after surgery (for example, lifelong annual reviews).

 

R

Carry out a comprehensive, multidisciplinary assessment for bariatric and metabolic surgery based on the individual’s needs. Ensure the multidisciplinary team within a specialist weight-management service includes or has access to health and social care professionals who have expertise in conducting medical, nutritional, psychological and surgical assessments in people living with obesity and type 2 diabetes and are able to assess whether surgery is suitable.

 

R

Patient care should be optimised while waiting for surgery in the tier 4 bariatric and metabolic surgery pathway (see Figure 3 in Components of an effective diabetes prevention programme). Optimisation could include pharmacological treatments to maintain or reduce weight.

 

Explain to the patient that they will need long-term follow-up care after bariatric and metabolic surgery. This should include:

  • lifelong annual checks to monitor diabetes status, even if remission is achieved
  • preventing post-surgery complications
  • education on life after surgery
  • understanding the need to continue lifelong dietary restraint, to optimise nutritional intake with reduced energy consumption.

References

26       National Institute for Health and Care Excellence (NICE). Overweight and obesity management. [cited 22 Jan 2025]. Available from url: https://www.nice.org.uk/guidance/ng246

42        NHS Health Scotland. Standards for the delivery of tier 2 and tier 3 weight management services for adults in Scotland. [cited 11 Sep 2024]. Available from url: https://www.publichealthscotland.scot/media/25614/standards-for-the-delivery-of-tier-2-and-tier-3-weight-management-services-for-adults-in-scotland-english-oct2019.pdf

43        The Scottish Government. A healthier future: type 2 diabetes prevention, early detection and intervention: framework. [cited 11 Sep 2024]. Available from url: https://www.gov.scot/publications/healthier-future-framework-prevention-early-detection-early-intervention-type-2/

52        Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care 2021;44(10):2438–44.

53        MacKay D, Chan C, Dasgupta K, Dominy C, Gagner M, Jin S, et al. Remission of type 2 diabetes: diabetes Canada practice guidelines expert working group. Canadian J Diabetes 2022;46(8):753-61.

54        Scottish Health Technologies Group (SHTG). A review of the clinical and cost effectiveness evidence for a digital type 2 diabetes remission programme in Scotland. [cited 11 Sep 2024]. Available from url: https://shtg.scot/our-advice/a-review-of-the-clinical-and-cost-effectiveness-evidence-for-a-digital-type-2-diabetes-remission-programme-in-scotland/